MRC1 and neoplasm: MMR‐deficient tumours exhibit several clinical characteristics that have implication for therapy, in particular with regard to the use of immune system modulators.8 Therefore, universal screening of CRC tumours, using microsatellite testing or immunohistochemistry (IHC) for the MMR proteins, has been recommended by several groups in Europe and the United States.9